Differences in Anti Malarial Antibody Concentrations and Specificities between Male and Female Ugandan Children

Brenda Apio Okech¹,²*, Corran P³, Todd J³, Agwang C², Riley EM⁴ and Egwang TG²

¹UVRI-IAVI HIV Vaccine Program, Uganda
²Med Biotech Laboratories, Uganda
³London School of Hygiene and Tropical Medicine, UK
⁴Institute of Immunology and Infection Research, School of Biological Sciences, University of Edinburgh, UK

Abstract
In Uganda malaria poses a formidable burden to an over-stretched and under-funded public health system trying to cope with other pressing health problems like HIV/AIDS and tuberculosis. Our earlier work on asexual blood stage malaria vaccine candidate merozoite surface protein (MSP119) provided a novel means of assessing antibody quality using altered proteins as well as ELISA competition assays with mouse monoclonal antibodies of known specificities. Our current hypothesis is that there is differential antibody level and quality between the sexes. This is based on earlier work in schistosomiasis showing higher levels of antibodies in females. Females have also been shown to have lower malaria parasite density although the explanation for this was thought to be hormonal.

In this study, levels of antibodies to several malaria antigens were measured in Ugandan school-going children in Northern Uganda, aged 7 to 16-years, to determine any difference in response between males and females. The qualities and specificities of MSP-119 antibodies in females and males were also determined by ELISA.

Overall females had higher levels and prevalence of antibodies to the merozoite proteins studied. These data suggest that dissection of the role of sex in naturally acquired immunity to malaria might identify drivers of the quality of the immune response. To our knowledge, this is the first report of higher levels of malaria antibodies to some asexual antigens in females compared to males in humans.

Introduction
Over one million deaths occur in Sub-Saharan Africa annually due to Plasmodium falciparum malaria (WHO, 2002). The deaths are a result of complications of malaria such as severe malaria-associated anaemia and cerebral malaria (WHO, 2000). In Uganda malaria poses a formidable burden to an over-stretched and under-funded public health system trying to cope with other pressing health problems like HIV/AIDS and tuberculosis. Twenty five to thirty percent of all outpatient visits and 300 infant deaths daily in Uganda are due to malaria alone, not to mention the significant proportion of low birth weight deliveries due to malaria during pregnancy [1,2]. A malaria vaccine that could interrupt the asexual blood stage in the host would prevent symptoms of malaria. A number of antigens have been proposed as vaccine candidates for this stage of the parasite. Some of the promising malaria vaccine candidates are serine rich antigen (SERA) [3], merozoite surface proteins 1, 2, 3 (MSP-1, MSP-2, MSP-3) [4-6], apical membrane protein 1 (AMA-1) [7], and ring infected erythrocyte surface antigen (RESA or Pf155) [8]. MSP-1 is proteolytically processed, post-translationally, in several stages. The primary processing step generates fragments of 83, 42, 38 and 30 kDa that persist on the surface of extracellular merozoites as a non-covalently linked complex held by the GPI anchor attached to the C-terminus of MSP-142 [9,10]. Secondary processing occurs during erythrocyte invasion and involves the cleavage of the membrane bound component of the 42 kDa complex at a single site to two smaller fragments of MSP-142 and MSP-133 [11,12]. Monoclonal antibodies to MSP-142 which inhibit MSP-1 secondary proteolytic processing also inhibit invasion [13]. Blocking monoclonal antibodies may interfere with the binding of inhibitory antibodies, allowing processing of MSP-142 and invasion of the erythrocyte to take place, while some are antibodies are neutral [14,15].

*Corresponding author: Brenda Apio Okech, UVRI-IAVI HIV Vaccine Program, Med Biotech Laboratories, Kampala, Uganda

Accepted: April 16, 2020

Published online: April 18, 2020

Citation: Okech BA, Corran P, Todd J, et al. (2020) Differences in Anti Malarial Antibody Concentrations and Specificities between Male and Female Ugandan Children. Arch Immunol 2(1):11-17
Our earlier work on asexual, blood stage malaria vaccine candidate merozoite surface protein (MSP-1\textsubscript{19}), provided a novel means of assessing antibody quality using altered proteins as well as ELISA competition assays with mouse monoclonal antibodies of known specificities [3]. Our current hypothesis is that there is differential antibody level and quality between the sexes. This is based on earlier work in schistosomiasis showing higher levels of antibodies in females [16]. Females have also been shown to have lower malaria parasite density although the explanation for this was thought to be hormonal [17]. Sex-based differences in immune responses to malaria infection have been reported in mice with females producing higher concentrations of cytokines such as IL-10 as well as higher total IgG and IgG1 compared to males [18].

In this study, levels of antibodies to several malaria antigens were measured in Ugandan school-going children, aged 7 to 16-years, to determine differential responses between males and females. The quality and specificities of MSP-1\textsubscript{19} antibodies in females and males were also determined. This is the first report to our knowledge of higher antibody levels to malaria merozoite surface antigens in females as well as a differential quality of IgG responses between the sexes in children.

Materials and Methods

Study site

The study took place in Atopi Parish, Maruzi County, in Apac District in Northern Uganda. Apac is located about 300 km from Kampala, the capital city of Uganda. The study site is located within a region of intense perennial malaria transmission whose malarialometric indices have been described previously [19]. Apac District covers an area of 6,684 sq km and ranges in altitude between 1,350, and 1,500 metres above sea level. The average annual rainfall is 1,350 mm and the average temperature is 27 °C. Luo is the main language spoken in the district and 98% of the population is of the Langi ethnic group, making it a more or less homogeneous society. Approx. 80 percent of Apac’s residents are engaged in subsistence farming. At the time of this study, the population was estimated at 676,244 according to the national census with a population density of 115 people per sq km. There are two major rainy seasons in this area, from March to May and then from July to August. And these are the peaks of malaria transmission. A study in 1995 showed that malaria transmission in Atopi Parish is hyper-endemic, and that acquired anti-parasite immunity appears by approximately seven years of age [19]. \textit{Plasmodium falciparum} is the major malaria parasite in this area.

Study design and study population

The design was a longitudinal, prospective cohort study of children attending Atopi Primary School in Atopi Parish. Briefly, ethical approval was obtained from the Uganda National Council for Science and Technology and parental consent was obtained prior to the enrolment of the children. A standard questionnaire, including recent clinical history and the use of anti-malarial drugs and protective anti-mosquito measures, was completed followed by an examination by a physician. At the initial visit, 183 children were seen, treated with a full curative dose of Fansidar\textsuperscript{®} to remove any prior malaria infection, and a whole blood (2 mls) sample was collected by finger prick using EDTA-containing vacutainers. Thin and thick blood smears were made on labelled glass slides. Serum was separated from cell pellets by centrifugation and both sera and cell pellets stored at -80 °C. The 159 children who had cleared all parasites from their blood by 2 weeks after Fansidar treatment were recruited. The target age of children who were recruited was 7 to 16-years. Out of the 159 children, 3 were excluded from all analyses because their age was out of range. A total of 156 children were therefore included in the study. The recruited children were followed-up fortnightly to assess reinfection and any associated morbidity. At each of the subsequent visits blood slides for malaria microscopy were made and the children examined and treated as appropriate. The study was carried out in year 2000.

Microscopy

Thick and thin blood smears for each child were prepared, air dried and Giemsa-stained for microscopic confirmation of \textit{P. falciparum} parasites. A rapid examination of thick films was carried out in Apac so that children with confirmed \textit{P. falciparum} infections received prompt treatment with anti-malarial drugs according to the national guidelines. Thin films were examined in detail in Kampala to identify the different species of malaria parasites while thick films were used for the enumeration of parasites. The parasite density per µl of blood was calculated from the number of parasites per 200 white blood cells (WBC), assuming an average normal WBC count of 8000/µL. A blood slide was declared negative after reading 100 high power fields.

Sickle cell genotyping

Sickle cell status of all the children was assessed through sickle cell hemoglobin electrophoresis. The children’s blood was centrifuged and the red cell pellets washed in saline and stored at -20 °C until ready for use. Hemolyzed patient samples and the haemoglobin controls (HbAA (normal adult blood), HbAS (blood from a subject with the sickle cell trait), HbAF (blood from an infant below 3 months), and HbAC (blood from a person with an HbAC trait) supplied by Helena Biosciences (Sunderland, UK) were resolved by electrophoresis on cellulose acetate plates at 350 V for 25 minutes in alkaline buffer (pH 8.4-8.6) and stained with Ponceau S for 5 minutes. The plates were de-stained, dried, and stored for permanent record keeping. The hemoglobin types were identified by comparing the migration of bands in the unknown specimens with the hemoglobin controls.

Enzyme linked immunosorbent assay (ELISA)

The following antigens were used in the study: Merozoite surface proteins MSP-1\textsubscript{19} (K1 sequence), MSP-1\textsubscript{19} (3D7 sequence), MSP-2 (FC27 sequence) and MSP-2 (3D7 sequence), SE36, SE50A, AMA-1, RESA and whole \textit{P. falciparum} schizont lysate. The \textit{P. falciparum} schizont lysate was made by rupturing...
mature percoll separated schizonts by repeated freezing and thawing using dry ice and water at 37°C. All other antigens are recombinant constructs expressed in *Escherichia coli*. Recombinant MSP-119 was prepared by standard techniques as a glutathione S-transferase (GST) fusion protein [20].

The quality of MSP-119 antibodies was measured using indirect ELISA with recombinant MSP-119 proteins in which specific residues had been mutated to destroy known targets of known non-protective (i.e., blocking or neutral) monoclonal antibodies [3,21]. These mutated MSP-119 antigens were also prepared as GST fusion proteins (as described by [21]). Altered protein M3 carries three amino acid substitutions—Glu to Tyr at residue 27, Leu to Arg at residue 31, and Gln to Leu at residue 43. The other two proteins carry these three substitutions and one additional substitution—Asn to Arg at residue 15 (M4X15) or Tyr to Ser at residue 34 (M4X34). The MSP antigens and GPI were donated by Anthony Holder. The SE50A and SE36 antigens were donated by Prof Toshiiro Horii.

Synthetic genes encoding SE47’ and SE50A representing the amino terminus and central domains, respectively, of SERAs were constructed using *E. coli* codons and the recombinant proteins were expressed in *E. coli* [22]. The synthetic gene construct encoding the recombinant antigen SE36 was identical to that encoding SE47 except that the 105-bp nucleotide sequence encoding a run of 35 serines were removed. The resulting SE36 is easier to purify and re-fold at a higher yield as described by [3].

The optimal antigen concentration for direct ELISA (1.0 µg/ml for all recombinant antigens and 1:1000 dilution for *P. falciparum* schizont lysate) were determined by checkerboard titration. All secondary antibodies used were conjugated to horseradish peroxidase (Dako Ltd, High Wycombe, UK). For the indirect ELISAs, rabbit anti-human IgG was used at a dilution of 1:5000. The plates used in all enzyme linked immunosorbent assays were flat-bottomed 96-well plates from Thermo Lab Systems (Immunolon® 4 plates, Dynatech, UK).

**Indirect ELISA**

The plates were coated overnight at 4°C with 100 µl of antigen at a concentration of 1 µg/ml in carbonate coating buffer of pH 9.6. The plates were then washed 3 times in PBS/Tween 20 and blocked with 1% bovine serum albumin (BSA) or 1% skimmed milk powder in PBS/T, 150 µl per well for 3 h or at room temperature. The plates were again washed 3 times with PBS/Tween 20. The test sera were added (100 µl per well) at dilutions of 1:1000 in 1% BSA in PBS/T and the plates incubated overnight at 4°C. After the plates were washed 4 times in PBS/Tween 20, 100 µl of horseradish peroxidase conjugated anti-human IgG diluted at 1:1000 in PBS/T was added per well and incubated at 37°C for 1 hour. The plates were washed 4 times, o-phenylenediamine (OPD) substrate (Sigma) was added and the plates were developed for 10 minutes. The reaction was stopped with 25 µl of 2M sulfuric acid and the plates read at 492 nm.

**Competition ELISA**

The quality of MSP-119 antibodies was also measured using competition ELISA with mouse monoclonal antibodies (MAbs) of known specificity [3]. MAbs 12.10 and 12.8 inhibit processing of MSP-119 to MSP-119 and MSP-119, and thus prevent erythrocyte invasion leading to protection from malaria, whereas MAbs 1E1 and 7.5 sterically interfere with binding of the inhibitory antibodies thereby blocking their function and permitting merozite invasion; MAbs 2F10 and 8A12 are neutral and have no effect on processing or invasion. MAbs were titrated by a direct ELISA for binding to wild-type MSP-119 antigens; each MAb was used in competition assays at a concentration that gave an OD just below the maximal OD for that antibody (i.e., just below the top of the linear part of the titration curve), such that any reduction in OD for the binding of the MAb was linearly associated with the amount of antibody bound. Microtiter plates were coated overnight with native or mutant MSP-119 (0.1 µg/ml) followed by washing. Serum at a dilution of 1:50 or 1:250 was added to duplicate wells, and the plates incubated overnight at 4°C. After washing, a fixed amount of mouse MAb was added, and the plates were incubated again overnight at 4°C. Rabbit anti-mouse immunoglobulins were used at a dilution 1:1000. The plates were washed, and binding of the MAb was detected with o-phenylenediamine and the reaction stopped with sulphuric acid and read as above. Sera were classified as being able to reduce MAb binding to MSP-119 by ≥ 50% at a dilution of 1:50 or 1:250 or as being non-competitive (< 50% inhibition of MAb binding at a dilution of 1:50).

**Statistical Analysis**

EPI Info 6 program (CDC Atlanta, Epidemiology Program Office, Atlanta, GA) was used for the entry of the malaria-related and laboratory data into the computer. All statistical analysis was carried out using STATA 8.1 (Statacorp, USA, 2004). The differences in mean serum levels of antibody in between male and female children were assessed using a non-parametric statistical method, Wilcoxon rank-sum (Mann-Whitney) test. Differences and associations of antibody levels and prevalence of positive antibodies by sex were assessed using chi-squared tests.

**Results**

**Comparisons of antibody responses by sex**

There were no significant differences between the sexes in age, village of residence, bed net usage, maximum malarial parasitemia, number of clinical episodes or antimalarial drug use over the study period (data not shown). However, there was a statistically significant difference between females and males in median antibody binding (expressed as optical density, OD) to some of the malaria antigens as shown in (Table 1). Antibody OD to MSP-119, MSP-119, MSP-2 FC27, MSP-2 3D7 but not RESA, AMA-1, and SE50A, were significantly higher in females than males. On the other hand, antibody levels to *P. falciparum* whole parasite lysate and SE36 antigens were significantly higher in males than females.

**Differences in fine specificities of the MSP119 response by sex**
The most significant difference between the sexes was in antibody OD to MSP-1₁₉. Antibodies to MSP-1₁₉ were assessed further by comparing the distribution of antibody specificities. The specificities were assayed by competition ELISA using mouse monoclonal antibodies of known functional specificities. The specificities were assessed further by comparing the distribution of antibody specificities (and putative inhibitory capacity) between male and female children aged 7-16-years in Atopi parish in Apac district.

**Discussion**

The major finding of this study was that female primary school-aged children had higher levels and higher prevalences of antibodies to malarial merozoite proteins studied than male children. There were no obvious differences in age or other demographic parameters that might have confounded this association. In Uganda survival is higher in females under 5-years [23]. Whilst there are behavioural explanations for sex or gender related differences in exposure to parasitic infection in some specific situations [24-26] there is considerable evidence that sex-determined differences in the strength of the immune response after exposure are substantially influenced by sex hormones.

There are many examples of sex-associated differences in immune responses [27,28] where behavioural differences can be ruled out, leaving the influence of sex hormones on the immune system as a likely driver of sex associated differences [29,30]. Administration of both measles and Diphtheria-Tetanus-Pertussis vaccines is associated with higher antibody response in females than males and has been linked to differences in the innate immune response, specifically Toll-like receptor 4 (TLR4) signalling [31] and a study of school children by found higher levels of TNF-α in non-obese females compared to their non-obese male counterparts [32]. However, these differences were seen in pre-pubertal school children as well as older students suggesting that factors other than hormonal differences may be at play.

With respect to malaria, Thai women vaccinated with the candidate SP f66 malaria vaccine higher antibody levels than men but also had more frequent adverse effects of vaccination [33], parasite densities are reportedly lower in females than males in endemic areas [17] and in males with higher dehydroepiandrosterone sulphate hormone levels [34]. Frequencies of cord blood regulatory T cell differed by infant sex, with significantly lower frequencies in female than in male neonates who were exposed to malaria in utero [35]. Studies in mice suggest that elevated testosterone concentrations in males reduce adaptive immunity and contribute to sex differences in immune response.
In summary, we have observed higher antibody levels and differences in antibody specificities for major merozoite antigens, some of which remain candidates for a malaria vaccine, between males and females. These observations may have implications for the development and deployment of malaria vaccines if they translate into sex-related differences in the response to malaria vaccination. Attention should be given to analysis of outcome of sex-related differences in the response to malaria vaccination and differences in antibody specificities for major merozoite antigens: Structure and role in immunity. Prog Allergy 41: 72-97.

Acknowledgement

This work was supported by a WHO/TDR grant to TG Egwang and an HHMI grant to TG Egwang.

References

1. Guyatt HL, Snow RW (2001) Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg 95: 569-576.

2. Kasumba IN, Nalunkuma AJ, Mujuzi G, et al. (2000) Low birthweight associated with maternal anemia and Plasmodium falciparum infection during pregnancy, in a peri-urban/urban area of low endemicity in Uganda. Ann Trop Med Parasitol 94: 7-13.

3. Aoki S, J Li, S Itagaki, et al. (2002) Serine repeat antigen (SERA5) of Plasmodium falciparum, and the acquired antibody titers correlated with serum inhibition of the parasite growth. J Biol Chem 277: 47533-47540.

4. Holder AA (1988) The precursor to major merozoite surface antigens: Structure and role in immunity. Prog Allergy 41: 72-97.
5. Oeuvray C, H Bouharoun-Tayyou, H Gras-Masse, et al. (1994) Merozoite surface protein-3: A malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.

6. Aucan C, Y Traore, F Tall, et al. (2000) High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect Immun 68: 1252-1258.

7. Stowers AW, MC Kennedy, BP Keegan, et al. (2002) Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70: 6961-6967.

8. Berzins K, H Perlmann, B Wahlin, et al. (1986) Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci U S A 83: 1065-1069.

9. Maitland K, Makanga M, Williams TN (2004) Falciparum malaria: Current therapeutic challenges. Curr Opin Infect Dis 17: 405-412.

10. Pachebat JA, IT Ling, MGrainger, et al. (2001) The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. Mol Biochem Parasitol 117: 83-89.

11. Blackman MJ, H Whittle, AA Holder (1991) Processing of the Plasmodium falciparum major merozoite surface protein-1: Identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol Biochem Parasitol 49: 35-44.

12. Blackman MJ, JA Chappell, S Shai, et al. (1993) A conserved parasite serine protease processes the Plasmodium falciparum merozoite surface protein-1. Mol Biochem Parasitol 62: 103-114.

13. Blackman MJ, TJ Scott-Finnigan, S Shai, et al. (1994) Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 180: 389-393.

14. Wilson CF, R Anand, JT Clark, et al. (1987) Topography of epitopes on a polymorphic schizont antigen of Plasmodium falciparum determined by the binding of monoclonal antibodies in a two-site radioimmunoassay. Parasite Immunol 9: 737-746.

15. Guevara Patino JA, AA Holder, J5 McBride, et al. (1997) Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 186: 1689-1699.

16. Naus CW, M Booth, FM Jones, et al. (2003) The relationship between age, sex, egg-count and specific antibody responses against Schistosoma mansoni antigens in an ugandan fishing community. Trop Med Int Health 8: 561-568.

17. Leenstra T, FO ter Kuile, SK Kariuki, et al. (2003) Dehydroepiandrosterone sulfate levels associated with decreased malaria parasite density and increased haemoglobin concentration in pubertal girls from western Kenya. J Infect Dis 188: 297-304.

18. Cernetich A, Garver LS, Jedlicka AE, et al. (2006) Involvement of gonadal steroids and gamma interferon in sex differences in response to blood-stage malaria infection. Infect Immun 74: 3190-3203.

19. Apio B, Nalunkuma A, Okello D, et al. (2000) Human IgG subclass antibodies to the 19 kilodalton carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1(19)) and predominance of the MAD20 allelic type of MSP1 in Uganda. East Afr Med J 77: 189-193.

20. Burghaus PA, AA Holder (1994) Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol 64: 165-169.

21. Uthaiplub C, B Aufiero, SE Syed, et al. (2001) Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol 307: 1381-1394.

22. Sugiyama T, Suzue K, Okamoto M, et al. (1996) Production of recombinant SERA proteins of Plasmodium falciparum in Escherichia coli by using synthetic genes. Vaccine 14: 1069-1076.

23. Elduma AH (2019) Equality Analysis of Main Health Indicators among Children under 5 Years in Uganda. Ethiopian J Health Sci 29: 215-222.

24. Grigg MJ, William T, Drakeley CJ, et al. (2014) Factors that are associated with the risk of acquiring Plasmodium knowlesi malaria in Sabah, Malaysia: a case-control study protocol. BMJ Open 4: e006004.

25. Hajissa K, Mohajar AEMA, Eshag HA, et al. (2018) Prevalence of schistosomiasis and associated risk factors among school children in Um-Asher Area, Khartoum, Sudan. BMC Res Notes 11: 779.

26. Wang Z, DU Z, Liu Y, et al. (2020) Comparison of the clinicopathological features and prognoses of patients with schistosomal and nonchistosomal colorectal cancer. Oncol Lett 19: 2375-2383.

27. Vemuri R, Sylvia KE, Klein SL, et al. (2019) The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin Immunopathol 41: 265-275.

28. Klein SL, Marriott I, Fish EN (2015) Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 109: 9-15.

29. Bernin H, Lotter H (2014) Sex bias in the outcome of human tropical infectious diseases: influence of steroid hormones. J Infect Dis 209: S107-S113.

30. Roberts CW, W Walker, J Alexander (2001) Sex-associated hormones and immunity to protozoan parasites. Clin Microbiol Rev 14: 476-488.

31. Noho-Konteh F, Adetifa IU, Cox M, et al. (2016) Sex-differential non-vaccine specific immunological effects of diphtheriataenus-pertussis and measles vaccination. Clin Infect Dis 63: 1213-1226.

32. Dixon D, Goldberg R, Schneiderman N, et al. (2004) Gender differences in TNF-alpha levels among obese vs nonobese Latino children. Eur J Clin Nutr 58: 696-699.

33. Migasena S, Heppner DG, Kyle DE, et al. (1997) SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand. Acta Trop 67: 215-227.

34. Kurts JD, R Mtali, FK Onyango, et al. (2001) Human resistance to Plasmodium falciparum increases during puberty and is predicted by dehydroepiandrosterone sulfate levels. Infect Immun 69: 123-128.

35. Prahl M, Jagannathan P, McIntyre TL, et al. (2017) Sex differences in the immune response and in infectious disease susceptibility have been well described, although the mechanisms underlying these. 2017 Sex Disparity in Cord. Blood FoxP3+ CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero. Open Forum Infect Dis 4.

36. Vom Steeg LG, Flores-Garcia Y, Zavala F, et al. (2019) Irradiated sporozoite vaccination induces sex-specific immune responses and protection against malaria in mice. Vaccine 37: 4468-4476.
37. Alelign A, Tekeste Z, Petros B (2018) Prevalence of malaria in Woreta town, Amhara region, Northwest Ethiopia over eight years. BMC Public Health 18: 990.

38. Cáceres Carrera L, Victoria C, Ramirez JL, et al. (2019) Study of the epidemiological behavior of malaria in the Darien Region, Panama. 2015-2017. PLoS One 14: e0224508.

39. Ntoumi F, Ekala MT, Makuwa M, et al. (2002) Sickle cell trait carriage: imbalanced distribution of IgG subclass antibodies reactive to Plasmodium falciparum family-specific MSP2 peptides in serum samples from Gabonese children. Immunol Lett 84: 9-16.

40. De Milito A (2004a) B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2: 11-21.

41. De Milito A, A Nilsson, K Titanji, et al. (2004b) Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 103: 2180-2186.